Pharmaceutical compositions comprising zinc
AssigneesZincum, Inc., Wayne State University
InventorsAnanda S. Prasad, Roy A. Varghese, Kenneth W. Brown, Richard P. Scheckenbach
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to pharmaceutical compositions comprising zinc, copper, at least one micronutrient, and a pharmaceutically acceptable excipient; and comprising administering, to a subject in need thereof, a pharmaceutical composition comprising zinc, copper, at least one micronutrient, and a pharmaceutically acceptable excipient.
Claims20
A method of increasing phosphorylation of insulin receptor tyrosine kinase, comprising administering, to a subject in need thereof, a pharmaceutical composition consisting of zinc;
- copper;
- selenomethionine;
- at least one micronutrient chosen from the group consisting of L-ascorbic acid, pyridoxine, biotin, vitamin B12, folic acid, pantothenic acid, niacin, and vitamin E;
- and a pharmaceutically acceptable excipient;
- wherein the zinc is present in the pharmaceutical composition in an amount of about 45 mg to about 100 mg.
A method for treating, reducing the severity of, reducing the incidence of, delaying the onset of, or reducing the pathogenesis of insulin resistance in a subject in need thereof, comprising administering to the subject a pharmaceutical composition consisting of:
- about 45 mg to about 100 mg zinc;
- about 0.5 mg to about 5 mg copper;
- about 25 mcg to about 200 mcg selenomethionine;
- about 50 mg to about 200 mg L-ascorbic acid;
- about 0.5 mg to about 5 mg pyridoxine;
- about 50 mcg to about 250 mcg biotin;
- about 50 mcg to about 250 mcg vitamin B12;
- about 100 μg to about 700 μg folic acid;
- about 5 mg to about 15 mg pantothenic acid;
- about 10 mg to about 30 mg niacin;
- about 5 IU to about 15 IU vitamin E;
- and
- a pharmaceutically acceptable excipient.
A method for treating, reducing the severity of, reducing the incidence of, or reducing the pathogenesis of type 2 diabetes in a subject in need thereof, comprising administering to the subject a pharmaceutical composition consisting of:
- about 0.5 mg to about 5 mg copper;
- about 25 mcg to about 200 mcg selenomethionine;
- about 50 mg to about 200 mg L-ascorbic acid;
- about 0.5 mg to about 5 mg pyridoxine;
- about 50 mcg to about 250 mcg biotin;
- about 50 mcg to about 250 mcg vitamin B12;
- about 100 μg to about 700 μg folic acid;
- about 5 mg to about 15 mg pantothenic acid;
- about 10 mg to about 30 mg niacin;
- about 5 IU to about 15 IU vitamin E;
- and
- a pharmaceutically acceptable excipient.
A method for treating, reducing the severity of, reducing the incidence of, or reducing the pathogenesis of type 2 diabetes in a subject in need thereof, comprising administering to the subject a pharmaceutical composition consisting of:
- about 45 mg to about 100 mg zinc;
- about 50 mg zinc;
- about 1.5 mg copper;
- about 100 mcg selenomethionine;
- about 120 mg L-ascorbic acid;
- about 2 mg pyridoxine;
- about 150 mcg biotin;
- about 150 mcg vitamin B12;
- about 400 μg folic acid;
- about 10 mg pantothenic acid;
- about 20 mg niacin;
- about 10 IU vitamin E;
- and
- a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.